Prospect for Pharmacological Therapies to Treat Skeletal Muscle Dysfunction
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605521298 | ||
| 003 | CHVBK | ||
| 005 | 20210128100739.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150301xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00223-014-9926-8 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00223-014-9926-8 | ||
| 245 | 0 | 0 | |a Prospect for Pharmacological Therapies to Treat Skeletal Muscle Dysfunction |h [Elektronische Daten] |c [Matthew Meriggioli, Ronenn Roubenoff] |
| 520 | 3 | |a Skeletal muscle weakness is a leading cause of mobility disability in the elderly (sarcopenia), as a complication of acute or chronic illness (cachexia), and due to inherited or acquired muscle diseases (muscular dystrophies, myositides, etc.). As of now, there are no approved drugs that can reliably increase muscle strength and function. However, with our understanding of the regulation of myocyte signaling and homeostasis evolving rapidly, experimental treatments are now entering the clinic. We review the current status of clinical research in pharmacological therapies for muscle disorders. | |
| 540 | |a Springer Science+Business Media New York, 2014 | ||
| 690 | 7 | |a Sarcopenia |2 nationallicence | |
| 690 | 7 | |a Cachexia |2 nationallicence | |
| 690 | 7 | |a Muscular dystrophies |2 nationallicence | |
| 690 | 7 | |a Muscle wasting |2 nationallicence | |
| 690 | 7 | |a Atrophy |2 nationallicence | |
| 700 | 1 | |a Meriggioli |D Matthew |u Department of Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge, MA, USA |4 aut | |
| 700 | 1 | |a Roubenoff |D Ronenn |u Department of Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge, MA, USA |4 aut | |
| 773 | 0 | |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 96/3(2015-03-01), 234-242 |x 0171-967X |q 96:3<234 |1 2015 |2 96 |o 223 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00223-014-9926-8 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a review-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00223-014-9926-8 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Meriggioli |D Matthew |u Department of Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge, MA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Roubenoff |D Ronenn |u Department of Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge, MA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 96/3(2015-03-01), 234-242 |x 0171-967X |q 96:3<234 |1 2015 |2 96 |o 223 | ||